The presentation will discuss the decision making process, methodology, competitive advantages, strategic implementation and challenges related to adapting and transitioning to a single use manufacturing system versus a fixed stainless steel system. In addition, the presentation will provide an update on the building process and highlight the theoretical business case versus the reality of implementation.
Catalent helps customers achieve competitive advantage by producing stable, high-yielding mammalian cell lines, and by providing robust bio-manufacturing services with industry leading timelines.
Dr. Michael Jenkins has been with Catalent Pharma Solutions for more than nine years. Before becoming General Manager of Catalent's Middleton, WI facility, he held senior roles in Commercial Operations and as Vice President of Business Development. Dr. Jenkins has previous industry experience in the development of mammalian cell culture and has also held technical roles at a plant transgenics company. He was awarded his Ph.D. by the Department of Molecular and Cellular Biology at the University of Arizona, with a minor in Biochemistry and has a B.S. in Microbiology from the University of Illinois at Champaign Urbana. Dr. Jenkins' areas of interest include traditional and transgenic biologics manufacturing platforms, the evaluation and establishment of innovative technologies in the biotechnology marketplace and where theseinterests merge to reduce the cost of developing and manufacturing products.
For more information on the 2012 Bio-Process Systems Alliance (BPSA) International Single-Use Summit, please visit http://www.bpsalliance.org/summit.html.
To schedule an interview with Dr. Jenkins during or after the conference, please contact Patricia McGee.
Companies in this press-release
